Phospho-Lck (Tyr505) (A3) rabbit mAb APC conjugate
Catalog #: 2304
20 μL is enough antibody for at least 20 Western blots.
Customers Also Viewed
Lck is a member of the Src family of non-receptor tyrosine kinases and plays a major role in T cell activation. Lck activates many downstream signaling pathways including Akt/mTOR, SAPK/JNK, PLCγ1, and RAS/MAPK. Phosphorylation of Lck at Tyr394 in the catalytic domain at the ATP-binding site stabilizes the open and active form, while phosphorylation at Tyr505 in the C-terminal domain promotes the closed, inactive conformation. Multiple small-molecule drugs used to treat leukemia have been shown to target inhibition of Lck, including imatinib and dasatinib. Lck is thus a promising target for suppressing T-cell responses for the treatment of inflammatory diseases or after organ transplantation.
|Cross Reactivity||Predicted to work with mouse, rat and other homologues.|
|Immunogen||A synthetic phospho-peptide corresponding to residues surrounding Tyr505 of human phospho Lck|
|Formulation||1X PBS, 0.09% NaN3, 0.2% BSA|
|Recommended Usage||For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells or 5 µL per 100 µL of staining volume. It is recommended that the reagent be titrated for optimal performance for each application.|
|Pseudonyms||Tyrosine-protein kinase Lck, Leukocyte C-terminal Src kinase, LSK, Protein YT16, T cell-specific protein-tyrosine kinase|
|References||Serafin V, Capuzzo G, Milani G, et al. (2017) Blood. 130: 2750-2761.
Lee KC, Ouwehand I, Giannini AL, et al. (2010) Leukemia. 24: 896-900.
Flow cytometric analysis of Daudi cells unstained and untreated as negative control (blue) or untreated (red) or treated with IFNa plus IL4 (green) using Phospho-LCK (Y505) antibody LCKY505-A3 PE conjugate. Cat. #2304.